These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16850796)

  • 1. [High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
    Einecke D
    MMW Fortschr Med; 2006 Jun; 148(24):4-5. PubMed ID: 16850796
    [No Abstract]   [Full Text] [Related]  

  • 2. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
    Einecke D
    MMW Fortschr Med; 2003 Dec; 145(51-52):38. PubMed ID: 14974329
    [No Abstract]   [Full Text] [Related]  

  • 4. [For coronary disease patients is certain: the lower the LDL the better].
    MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
    [No Abstract]   [Full Text] [Related]  

  • 5. [60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
    MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732408
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comment from the cardiologic viewpoint].
    Lüscher TF
    Praxis (Bern 1994); 2009 Feb; 98(3):129-30. PubMed ID: 19180438
    [No Abstract]   [Full Text] [Related]  

  • 8. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
    MMW Fortschr Med; 2005 Nov; 147(45):54. PubMed ID: 16320655
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
    März W
    MMW Fortschr Med; 2003 Dec; 145(50):46-9. PubMed ID: 14963971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
    Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
    Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 15. [Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
    Kuznetsova MA; Vaulin NA; Masenko VP; Gratsianskiĭ NA
    Kardiologiia; 2010; 50(2):21-5. PubMed ID: 20146674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
    Clearfield M
    Curr Atheroscler Rep; 2006 Jan; 8(1):7-8. PubMed ID: 16455005
    [No Abstract]   [Full Text] [Related]  

  • 17. High-intensity statin treatment for coronary heart disease.
    Sacks FM
    JAMA; 2004 Mar; 291(9):1132-4. PubMed ID: 14996784
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2011; 75(2):398-406. PubMed ID: 21157106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
    Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
    Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
    Lablanche JM; Leone A; Merkely B; Morais J; Alonso J; Santini M; Eha J; Demil N; Licour M; Tardif JC;
    Arch Cardiovasc Dis; 2010 Mar; 103(3):160-9. PubMed ID: 20417447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.